AMAG Pharmaceuticals, Inc.

Lead Plaintiff Deadline: May 18, 2010 + Deadline passed

Summary of Case:

A securities class action has been filed against AMAG Pharmaceuticals, Inc. (AMAG) ("AMAG" or the "Company") on behalf of all securities purchasers on January 21, 2010 ("Class Period"), in the United States District Court of Massachusetts.

The complaint alleges that on or about January 21, 2010, the Registration Statement (the "Registration Statement") with respect to the Secondary Offering became effective and 3.6 million shares of AMAG common stock were sold to the public at $48.25 per share, thereby raising more than $173 million.

The complaint also alleges that the Registration Statement failed to disclose that users of the Company's primary drug, Feraheme, had suffered adverse reactions, some requiring hospitalization. On February 4, 2010, Carol Werther, a Summer Street analyst downgraded AMAG from buy to neutral. In a note to clients she wrote, "We are aware of several patients hospitalized with anaphylactiod reactions to Feraheme. We are aware of one death that may or may not be directly related to Feraheme." On disclosure of this news, AMAG's stock fell over $7.00 per share to close at $38.12 per share.

The complaint further alleges that the Registration Statement failed to disclose that the effect of the Company's rebate program would be to front load sales into the fourth quarter causing sales to drop off after the Offering was completed. On this disclosure, AMAG's stock price once again declined, closing on March 1 at $34.17 per share down $4.02 from the previous day's closing price of $38.19.

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.